大行評級|建銀國際:上調阿里健康目標價至4.8港元 上調2025至27財年每股盈測
建銀國際發表研報指,阿里健康2025上半財年銷售額按年增長10.2%至143億元,低於該行預期的152億元,主要由於期內產品組合重心從藥品轉向醫療器材及保健品,同時亦推動經營利潤率上升,釋放平台業務發展潛力。
通過阿里健康收購阿里媽媽醫療健康類目獨家營銷審核權,建銀國際相信可加深與商户的關係,令公司將發展方向轉至非製藥產品時,更能快速增長,目前預測電商平台業務在下財半年可維持按年增長40%以上。相應該行亦將阿里健康2025至2027財年每股盈利預測上調9.2%,目標價由4.4港元上調至4.8港元,評級“跑贏大市”。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.